The Shenzhen University of Advanced Technology (SUAT), in collaboration with Fosun Pharma and Huawei Technologies, has launched the GBA AI+ Medical Collaborative Innovation Center in Guangming District, as announced by the university on its official WeChat account.

This initiative aims to revolutionize the application of AI technology in the medical and pharmaceutical sectors in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA).

The collaborative effort between the three parties will focus on creating an integrated research platform that merges AI technology with biomedicine, diagnostics, and medical processes. Over the next three years, the partners plan to develop five AI-based sub-platforms, including AI-assisted drug design, translational medicine, clinical trials, medical decision-making, and medical equipment innovation.

The construction goals of the AI innovation center align well with Guangming District's emphasis on innovation collaboration and industrial integration, district officials said at the launch event, adding that the district supports the construction of the AI innovation center and will provide comprehensive services related to policies, space, and equipment.

The center aims to provide top-tier AI medical services to local pharmaceutical enterprises, universities, and research institutions, thereby accelerating the development and commercialization of innovative drugs and medical technologies in China.